title: Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
abstract: The ephrinA1 ligand exerts antioncogenic effects in tumor cells through activation and downregulation of the EphA2 receptor and has been described as a membrane-anchored protein requiring clustering for function. However, while investigating the ephrinA1/EphA2 system in the pathobiology of glioblastoma multiforme (GBM), we uncovered that ephrinA1 is released from GBM and breast adenocarcinoma cells as a soluble, monomeric protein and is a functional form of the ligand in this state. Conditioned media containing a soluble monomer of ephrinA1 caused EphA2 internalization and downregulation, dramatic alteration of cell morphology and suppression of the Ras-MAPK pathway. Moreover, soluble monomeric ephrinA1 was functional in a physiological context, eliciting collapse of embryonic neuronal growth cones. We also found that ephrinA1 is cleaved from the plasma membrane of GBM cells, an event which involves the action of a metalloprotease. Thus, the ephrinA1 ligand can, indeed, function as a soluble monomer and may act in a paracrine manner on the EphA2 receptor without the need for juxtacrine interactions. These findings have important implications for further deciphering the function of these proteins in pathology and physiology, as well as for the design of ephrinA1-based EphA2-targeted antitumor therapeutics.
authors.affiliation: Department of Neurosurgery, Brain Tumor Center of Excellence, Wake Forest University School of Medicine, Comprehensive Cancer Center, Winston-Salem, NC 27157, USA.
authors.forename: J
authors.initials: J
authors.lastname: Wykosky
authors.forename: E
authors.initials: E
authors.lastname: Palma
authors.forename: D M
authors.initials: DM
authors.lastname: Gibo
authors.forename: S
authors.initials: S
authors.lastname: Ringler
authors.forename: C P
authors.initials: CP
authors.lastname: Turner
authors.forename: W
authors.initials: W
authors.lastname: Debinski
mesh_terms: D055592:Biophysical Phenomena; D045744:Cell Line, Tumor; D036382:Ephrin-A1 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D036104:Receptor, EphA2 / Q000235:genetics / Q000378:metabolism*; D012995:Solubility; D014162:Transfection
chemical_list: D036382:Ephrin-A1; D008024:Ligands; D036104:Receptor, EphA2
references.citation: Mol Cancer Res. 2005 Oct;3(10):541-51
references.pmid: 16254188
references.citation: Nat Cell Biol. 2001 May;3(5):527-30
references.pmid: 11331884
references.citation: Genes Dev. 1998 Mar 1;12(5):667-78
references.pmid: 9499402
references.citation: Int J Cancer. 1998 Mar 2;75(5):780-6
references.pmid: 9495249
references.citation: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3208-18
references.pmid: 18089715
references.citation: Eur J Neurosci. 1997 Jan;9(1):177-88
references.pmid: 9042581
references.citation: J Biol Chem. 2002 Dec 6;277(49):46974-9
references.pmid: 12351647
references.citation: Cancer Res. 2001 Mar 1;61(5):2301-6
references.pmid: 11280802
references.citation: Mol Cancer Res. 2002 Nov;1(1):2-11
references.pmid: 12496364
references.citation: Cancer Res. 2006 Jul 15;66(14):7050-8
references.pmid: 16849550
references.citation: EMBO J. 1994 Aug 15;13(16):3757-62
references.pmid: 8070404
references.citation: Clin Cancer Res. 2002 Aug;8(8):2714-24
references.pmid: 12171905
references.citation: Growth Factors. 2006 Jun;24(2):121-36
references.pmid: 16801132
references.citation: Oncol Rep. 2006 Apr;15(4):831-6
references.pmid: 16525667
references.citation: Prostate. 1999 Dec 1;41(4):275-80
references.pmid: 10544301
references.citation: Exp Neurol. 2002 Nov;178(1):21-32
references.pmid: 12460605
references.citation: Science. 2000 Aug 25;289(5483):1360-5
references.pmid: 10958785
references.citation: Neuron. 2005 Jul 7;47(1):57-69
references.pmid: 15996548
references.citation: Mol Cell Biol. 1990 Nov;10(11):5830-8
references.pmid: 2233719
references.citation: J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93
references.pmid: 17971532
references.citation: Oncogene. 2004 Feb 19;23(7):1448-56
references.pmid: 14973554
references.citation: J Clin Invest. 1992 Aug;90(2):405-11
references.pmid: 1644913
references.citation: Cancer Cell. 2005 Aug;8(2):111-8
references.pmid: 16098464
references.citation: Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102
references.pmid: 15249202
references.citation: Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86
references.pmid: 12094214
references.citation: Cell. 1998 May 29;93(5):741-53
references.pmid: 9630219
references.citation: Nat Neurosci. 2004 May;7(5):501-9
references.pmid: 15107857
references.citation: Mech Dev. 1998 Oct;77(2):201-4
references.pmid: 9831653
references.citation: Ann N Y Acad Sci. 2003 May;995:22-38
references.pmid: 12814936
references.citation: Nature. 2001 Dec 20-27;414(6866):933-8
references.pmid: 11780069
references.citation: Science. 1995 Apr 28;268(5210):567-9
references.pmid: 7536959
references.citation: J Biol Chem. 1995 Mar 10;270(10):5636-41
references.pmid: 7890684
references.citation: Cancer Res. 2002 May 15;62(10):2840-7
references.pmid: 12019162
references.citation: Cell. 1995 Aug 11;82(3):359-70
references.pmid: 7634326
references.citation: Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75
references.pmid: 15928710
references.citation: Kidney Int Suppl. 1996 Dec;57:S73-81
references.pmid: 8941926
references.citation: Oncogene. 2000 Dec 7;19(52):6043-52
references.pmid: 11146556
references.citation: J Mol Med (Berl). 1997 Aug;75(8):576-86
references.pmid: 9297625
references.citation: Clin Cancer Res. 2004 Aug 1;10(15):5145-50
references.pmid: 15297418
references.citation: Nat Cell Biol. 2000 Feb;2(2):62-9
references.pmid: 10655584
references.citation: Dev Cell. 2001 Jul;1(1):83-92
references.pmid: 11703926
references.citation: Blood. 2000 Jan 1;95(1):221-30
references.pmid: 10607706
references.citation: Cell. 2005 Apr 8;121(1):127-39
references.pmid: 15820684
references.citation: Trends Neurosci. 2002 Mar;25(3):145-9
references.pmid: 11852146
references.citation: Cell. 1996 Sep 6;86(5):755-66
references.pmid: 8797822
references.citation: Pathol Oncol Res. 2004;10(1):26-33
references.pmid: 15029258
references.citation: Cancer Res. 2006 Nov 1;66(21):10315-24
references.pmid: 17079451
references.citation: Science. 1994 Nov 4;266(5186):816-9
references.pmid: 7973638
references.citation: Mol Cancer Res. 2002 Nov;1(1):79-87
references.pmid: 12496371
references.citation: Annu Rev Biochem. 1988;57:285-320
references.pmid: 3052274
references.citation: Trends Biochem Sci. 2005 Jul;30(7):413-22
references.pmid: 15949939
references.citation: Clin Exp Metastasis. 2003;20(1):59-68
references.pmid: 12650608
references.citation: J Neurooncol. 2001 Jun;53(2):213-35
references.pmid: 11716072
references.citation: Am J Pathol. 2003 Dec;163(6):2271-6
references.pmid: 14633601
references.citation: Biochim Biophys Acta. 2005 Aug 1;1751(1):110-7
references.pmid: 16054021
references.citation: Cancer Gene Ther. 2004 Nov;11(11):757-66
references.pmid: 15359289
references.citation: Mol Cell Biochem. 2003 Nov;253(1-2):269-85
references.pmid: 14619979